CapsoVision (CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence technologies that are deployed in its capsule endoscopy solutions, priced 5.5M shares at $5.00. The deal size was increased to 5.5M shares from 5.25M and priced at the low end of the $5.00-$5.50 range. Benchmark and Roth Capital are acting as joint book running managers for the offering.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks